Systems and methods for delivery of drugs

• US 20090263346A1
• Filed: 12/04/2008
• Published: 10/22/2009
• Est. Priority Date: 12/05/2006
• Status: Abandoned Application

• Current Assignee: Landec Corporation
• Original Assignee: Landec Corporation
• Inventors: Bell, Adam, Bitler, Steven, Dai, Wei-Guo, Taft, David, Tzannis, Stelios, Zheng, Qiang, Ottensmann, Sandra
• Application Number:
  US12/315,876
• Publication Number:
  US 20090263346A1
• Time in Patent Office: Days
• US Class Current: 424/78.170
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/146 with organic macromolecular compounds
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Abstract

Systems and methods for delivering drugs. Crystalline polymeric systems, referred to as CYC carriers, are associated with the drugs, through chemical bonding or through physical association. The crystallinity of the CYC carriers results from the presence of crystallizable side chains, for example long chain n-alkyl moieties, which results in relatively low and sharp melting temperatures. One class of CYC carriers, referred to as CYSC polymers, have a majority of the crystallizable side chains pendant from the polymer backbone. Another class of CYC carriers, referred to as ECC polymers, have a majority of the crystallizable side chains attached to terminal units of the polymer backbone. The ECC polymers can for example be obtained by modification of PLGA polymers. The CYC carriers in another class are non-polymeric. Some CYC carriers, referred to as CYC assemblies, have enhanced crystallinity as a result of the physical association of crystallizable moieties which are present in different types of molecule, for example between a polymer containing crystallizable moieties and a monomer containing crystallizable moieties. Preferably the CYC carrier is bioerodable.

Claims

1. A pharmaceutical formulation which comprises a CYC carrier and a drug associated with the CYC carrier, the CYC carrier being an ECC polymer which

(A) comprises a plurality of polymeric molecules which have a backbone which comprises terminal units having the formula

—

Y_term-b-Cy 

 

(2)

where Y_term is a moiety at the end of the backbone, and

b is a bond or moiety which links the Cy moiety to Y_term, and

Cy is a moiety which is associated with other Cy moieties to provide the CYC polymer with crystallinity;

the Cy moieties in said terminal units providing at least 50% by weight of the Cy moieties in the polymeric molecules, and

(B) has a crystalline melting temperature, Tp, of at least 0°

C. and a heat of fusion, Δ

H, of at least 3 J/g which result from association of the Cy moieties, Tp and Δ

H being measured on a differential scanning calorimeter (DSC) as hereinbefore described.

2. A formulation according to claim 1 wherein said terminal units comprise moieties having the formula

-Qx(-b-Cy)_q 

 

(Q2)

wherein Qx is a moiety having a valence of at least (q+1) and q is at least 2.

3. A formulation according to claim 2 wherein q is 3, 4, 5 or 6.

4. A formulation according to claim 1 wherein the backbone is bioerodable and comprises linkages having the formula

-D_nd-Q-E_ne- 

 

(Q1)

where

Q is —

O—

, —

NH—

or —

S—

,

nd is 0 or 1,

ne is 0 or 1,

D is —

CO—

, and

E is —

CO—

or —

CO—

O—

.

5. A formulation according to claim 1 wherein the ECC polymer

(A) comprises a plurality of polymeric molecules each of which consists essentially of

(i) a polymer backbone which comprises a plurality of repeating units having the formula

—

CF¹F²—

CO—

O—

 

 

(1)

wherein

F¹ is hydrogen and F² is hydrogen or methyl, the repeating units being the same or different, and

(ii) at least one terminal unit which has the formula

-b-Cy 

 

(2)

wherein

Cy is an n-alkyl moiety containing 18-24 carbon atoms, and

b is a bond or a moiety which has a valence of at least 2, which links the Cy moiety to the polymer backbone, and which optionally contains one or more additional Cy moieties;

(B) has a crystalline melting temperature, Tp, of at least 40°

C., an onset of melting temperature, To, such that the value of (Tp−

To) is less than Tp^0.7, and a heat of fusion of at least 5 J/g, Tp, To and Δ

H being measured on a differential scanning calorimeter (DSC) as hereinbefore described.

(C) has a number average molecular weight, Mn, measured as hereinbefore described, of less than 10,000.

6. A formulation according to claim 5 wherein the drug is risperidone or diclofenac sodium.

7. A formulation according to claim 5 wherein at least some of the polymeric molecules contain at least three Cy moieties, and the polymer has a heat of fusion of at least 10 J/g.

8. A formulation according to claim 5 wherein at least one of the Cy moieties includes a polyoxyalkylene moiety.

9. A formulation according to claim 5 wherein the drug and the polymer are such that, when they are formulated into a release sample in the form of a thin flat disc by the procedure described in the Examples above and tested by each of the two release tests described in the Examples above, the drug is released, in at least one of the two tests, according to at least one of paragraphs (a)-(c) below

(a) at a substantially constant rate over a period of at least 10 days in the first 20 days, and in a total amount less than 30%,

(b) in a total amount less than 30% over the first 10 days, and

(c) at a substantially constant rate over the first 10 days and in a total amount less than 20% over the first 20 days.

10. A formulation according to claim 5 which,

(i) when tested by a release test in which the formulation is exposed to a buffer solution which is maintained at a pH of 5.5, releases the drug according to at least one of paragraphs (a)-(c) below

(a) at a substantially constant rate over a period of at least 10 days in the first 20 days, and in a total amount less than 30%,

(b) in a total amount less than 30% over the first 10 days, and

(c) at a substantially constant rate over the first 10 days, and in a total amount less than 20% over the first 10 days;

or

(ii) when tested by a release test in which the formulation is exposed to a buffer solution which is maintained at a pH of 7.4, releases the drug

(a) at a substantially constant rate over a period of at least 10 days in the first 20 days, and in a total amount less than 30% over the first 20 days, and

(b) in a total amount less than 30% over the first 20 days.

11. A formulation according to claim 5 wherein the ECC polymer

(A) consists essentially of a plurality of polymeric molecules each of which consists essentially of

(i) a polymer backbone which consists essentially of a plurality of repeating units having the formula

—

CH₂—

CO—

O—

 

 

(1A)

and a plurality of repeating units having the formula

—

CH(CH₃)—

CO—

O—

 

 

(1B)

and

(ii) a plurality of terminal units each of which has the formula

-b-Cy 

 

(2)

wherein

Cy is an n-alkyl moiety containing 18-24 carbon atoms, and

b is a bond or a moiety which has a valence of at least 2, which links the Cy moiety to the polymer backbone and which optionally contains additional Cy moieties;

(B) has a crystalline melting temperature, Tp, of at least 40°

C., an onset of melting temperature, To, such that the value of (Tp−

To) is less than 10°

C., and a heat of fusion of at least 5 J/g, Tp, To and the heat of fusion being measured on a differential scanning calorimeter (DSC) as hereinbefore described;

(C) has a number average molecular weight, Mn, measured as hereinbefore described, of less than 8,000.

12. A formulation according to claim 11 wherein the polymer has at least one of the following characteristics

(i) it has a molecular weight less than 5000,

(ii) it contains 2-30 molar percent of the terminal units,

(iii) it contains 10-40% by weight of Cy moieties,

(iv) at least one of the terminal units has a formula selected from the group consisting of

-Cy 

 

(2A)

—

CO—

O-Cy 

 

(2B)

—

R_pbalc—

CO-Cy 

 

(2C)

where R_pbalc is the residue of a polyol,

(v) at least one of the terminal units has a formula selected from the group consisting of

—

CH₂—

CH(OH)—

CH₂O—

CO-Cy

and

—

CH₂—

CH(O—

CO-Cy)-CH₂—

O—

CO-Cy,

(vi) at least some of the polymeric molecules contain at least three Cy moieties, and

(vii) it contains less than 170 repeating units of the formulas (1A) and (1B).

13. A method of making a pharmaceutical formulation which comprises mixing a drug with an ECC polymer as defined in claim 1.

14. A method according to claim 13 wherein the drug has a maximum temperature to which it can be exposed without damage, and the drug is mixed with the polymer at a temperature at which the polymer is liquid and which is below the maximum temperature.

15. A method according to claim 14 wherein the mixing is carried out in the absence of any liquid other than the polymer.

16. A pharmaceutical formulation which comprises a CYC carrier and a drug associated with the CYC carrier, the CYC carrier being a block copolymer comprising a plurality of block copolymer molecules which comprise a first polymeric block and a second polymeric block,

the first polymeric block having a backbone which is bioerodable and which comprises linkages having the formula

-D_nd-Q-E_ne- 

 

(Q1)

where

Q is —

O—

, —

NH—

or —

S—

,

nd is 0 or 1,

ne is 0 or 1,

D is —

CO—

, and

E is —

CO—

or —

CO—

O—

and the second polymeric block comprising repeating units having the formula

17. A formulation according to claim 16 wherein the first polymeric block is a PLGA, PLA or PGA block.

18. A pharmaceutical formulation which comprises a CYC carrier and a drug associated with the CYC carrier, the CYC carrier being a non-polymeric compound which

(A) has the formula

Q(-b-Cy)_q 

 

(4)

wherein q is least 2, e.g. 3-8,

Q is a moiety having a valence of at least q,

b is a bond or a moiety linking the Cy moiety to the Q moiety, and

Cy is a moiety which is associated with other Cy moieties to provide the

CYC polymer with crystallinity, and

(B) has a crystalline melting temperature, Tp, of at least 0°

C. and a AH of at least 3 J/g which results from association of the Cy moieties; and

19. A pharmaceutical formulation which comprises a CYC carrier and a drug associated with the CYC carrier, the CYC carrier being a CYC assembly of (i) a polymer which is a CYC polymer as hereinbefore defined except that the polymer does not necessarily have a Tp of at least 0°

C. and a Δ

H of at least 4 J/g, and (ii) a compound which contains a Cy moiety and which is intimately mixed with the polymer but is not covalently linked to the polymer, the assembly having a crystalline melting temperature, Tp, of at least 0°

C. and a Δ

H of at least 3 J/g which results from association of the Cy moieties.

20. A pharmaceutical formulation which comprises a CYC carrier and a drug associated with the CYC carrier, the CYC carrier being an SSP polymer, an SSP polymer being defined as a polymer which

(1) has a crystalline melting temperature, Tp, of at least 25°

C., and a Δ

H of at least 5 J/g; and

(2) comprises polymeric molecules having a backbone which comprises

(a) repeating units which do not contain hydrophilic moieties, and have the formula (1) below

28. An SSP polymer as defined in claim 20.

21. A pharmaceutical formulation which comprises a CYC carrier as hereinbefore defined and a drug associated with the CYC carrier.

22. A formulation according to claim 21 wherein the CYC carrier and the drug form a single phase or a uniform two-phase mixture.

24. A method of releasing a drug from a pharmaceutical formulation as claimed in claim 21 which comprises subjecting the formulation to conditions which change the association between the drug and the CYC carrier.

25. A method of treating a condition in a mammal which comprises administering to the mammal a pharmaceutical formulation as defined in claim 21, the formulation being administered as such or being formed during or after administration.

26. A method of making a pharmaceutical formulation as claimed in claim 21 which comprises mixing the drug and the CYC carrier, wherein the drug has a maximum temperature to which it can be exposed without damage, and the drug is mixed with the carrier at a temperature at which the carrier is liquid and which is below the maximum temperature.

27. A method according to claim 26 wherein the mixing is carried out in the absence of any liquid other than the carrier.